Fannin Partners, LLC today announced two new grants from the Congressionally Directed Medical Research Programs (CDMRP) and the Faris Foundation to advance development of a targeted Raptamer-Drug Conjugate (RapDC) therapy for Ewing sarcoma [Fannin Partners, LLC (PR Newswire)] Press Release
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.